CANCER:

Lung Adenocarcinoma

Related cancers:

‹

Non Small Cell Lung Cancer (2603)

Lung Non-Squamous Non-Small Cell Cancer (86)

Lung Non-Small Cell Squamous Cancer (83)

Non Small Cell Lung Cancer (2603)

Lung Non-Squamous Non-Small Cell Cancer (86)

Lung Non-Small Cell Squamous Cancer (83)

›

CD276 underexpression + EGFR mutation CD276 underexpression + EGFR mutation	Lung Adenocarcinoma LUAD	CD276 underexpression + EGFR mutation CD276 underexpression + EGFR mutation	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C3 – Early Trials World J Surg Oncol - 1 week (NewC3)	EGFR inhibitor Sensitive: C3 – Early Trials World J Surg Oncol - 1 week - (New C3)
EGFR V786M EGFR V786M	Lung Adenocarcinoma LUAD	EGFR V786M EGFR V786M	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C4 – Case Studies Front Oncol - 1 week (NewC4)	EGFR inhibitor Sensitive: C4 – Case Studies Front Oncol - 1 week - (New C4)
LMO7-ALK rearrangement LMO7-ALK rearrangement	Lung Adenocarcinoma LUAD	LMO7-ALK rearrangement LMO7-ALK rearrangement	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C4 – Case Studies Front Oncol - 1 week (NewC4)	crizotinib Sensitive: C4 – Case Studies Front Oncol - 1 week - (New C4)
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR inhibitor Sensitive: C3 – Early Trials PLoS One - 3 weeks (NewC3)	EGFR inhibitor Sensitive: C3 – Early Trials PLoS One - 3 weeks - (New C3)
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval	nintedanib Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	DP Sensitive: A2 - Guideline	DP Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	GC Sensitive: A2 - Guideline	GC Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	cisplatin + pemetrexed Sensitive: A2 - Guideline	cisplatin + pemetrexed Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	erlotinib Sensitive: B - Late Trials	erlotinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	erlotinib Resistant: B - Late Trials	erlotinib Resistant: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
HER-2 exon 20 insertion + TMB-L + PD-L1 negative HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma LUAD	HER-2 exon 20 insertion + TMB-L + PD-L1 negative HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma LUAD	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C1 - Off-label	bevacizumab + erlotinib Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	atezolizumab Sensitive: C1 - Off-label	atezolizumab Sensitive: C1 - Off-label
MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	tepotinib Sensitive: C1 - Off-label	tepotinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label	osimertinib Resistant: C1 - Off-label
BRAF V600E BRAF V600E	Lung Adenocarcinoma LUAD	BRAF V600E BRAF V600E	Lung Adenocarcinoma LUAD	trametinib + dabrafenib Sensitive: C1 - Off-label	trametinib + dabrafenib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Lung Adenocarcinoma LUAD	ATM mutation ATM mutation	Lung Adenocarcinoma LUAD	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label	osimertinib Resistant: C1 - Off-label
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C1 - Off-label	osimertinib Sensitive: C1 - Off-label
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C1 - Off-label	erlotinib Sensitive: C1 - Off-label
RET fusion RET fusion	Lung Adenocarcinoma LUAD	RET fusion RET fusion	Lung Adenocarcinoma LUAD	pralsetinib Sensitive: C1 - Off-label	pralsetinib Sensitive: C1 - Off-label
ALK positive ALK positive	Lung Adenocarcinoma LUAD	ALK positive ALK positive	Lung Adenocarcinoma LUAD	lorlatinib Sensitive: C1 - Off-label	lorlatinib Sensitive: C1 - Off-label
MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	capmatinib Sensitive: C1 - Off-label	capmatinib Sensitive: C1 - Off-label
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab Sensitive: C2 – Inclusion Criteria	bevacizumab Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C2 – Inclusion Criteria	erlotinib Sensitive: C2 – Inclusion Criteria
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	EGFR wild-type EGFR wild-type	Lung Adenocarcinoma LUAD	rivoceranib Sensitive: C2 – Inclusion Criteria	rivoceranib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	cetuximab + afatinib Sensitive: C3 – Early Trials	cetuximab + afatinib Sensitive: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion + PD-L1 overexpression EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + PD-L1 overexpression EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab + afatinib Sensitive: C3 – Early Trials	bevacizumab + afatinib Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR-RAD51 fusion EGFR-RAD51 fusion	Lung Adenocarcinoma LUAD	EGFR-RAD51 fusion EGFR-RAD51 fusion	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
EGFR exon 18-25 duplication EGFR exon 18-25 duplication	Lung Adenocarcinoma LUAD	EGFR exon 18-25 duplication EGFR exon 18-25 duplication	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	bevacizumab + osimertinib Resistant: C3 – Early Trials	bevacizumab + osimertinib Resistant: C3 – Early Trials
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	trastuzumab + pertuzumab Sensitive: C3 – Early Trials	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
SNX20 overexpression + PD-L1 overexpression SNX20 overexpression + PD-L1 overexpression	Lung Adenocarcinoma LUAD	SNX20 overexpression + PD-L1 overexpression SNX20 overexpression + PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Lung Adenocarcinoma LUAD	TP53 mutation TP53 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Adenocarcinoma LUAD	EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C3 – Early Trials	osimertinib Sensitive: C3 – Early Trials
OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	carboplatin + pemetrexed Sensitive: C3 – Early Trials	carboplatin + pemetrexed Sensitive: C3 – Early Trials
MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	carboplatin + pemetrexed Sensitive: C3 – Early Trials	carboplatin + pemetrexed Sensitive: C3 – Early Trials
MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	cisplatin Sensitive: C3 – Early Trials	cisplatin Sensitive: C3 – Early Trials
OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	cisplatin Sensitive: C3 – Early Trials	cisplatin Sensitive: C3 – Early Trials
EGFR mutation + MDM4 32C>A EGFR mutation + MDM4 32C>A	Lung Adenocarcinoma LUAD	EGFR mutation + MDM4 32C>A EGFR mutation + MDM4 32C>A	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
KEAP1 mutation + MSI-L/dMMR KEAP1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	KEAP1 mutation + MSI-L/dMMR KEAP1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
IFI27 underexpression IFI27 underexpression	Lung Adenocarcinoma LUAD	IFI27 underexpression IFI27 underexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR overexpression EGFR overexpression	Lung Adenocarcinoma LUAD	EGFR overexpression EGFR overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials	pemetrexed Sensitive: C3 – Early Trials
ALK positive ALK positive	Lung Adenocarcinoma LUAD	ALK positive ALK positive	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials	pemetrexed Sensitive: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR exon 21 mutation EGFR exon 21 mutation	Lung Adenocarcinoma LUAD	EGFR exon 21 mutation EGFR exon 21 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR mutation + PIK3CA mutation EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma LUAD	EGFR mutation + PIK3CA mutation EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR mutation + TP53 mutation EGFR mutation + TP53 mutation	Lung Adenocarcinoma LUAD	EGFR mutation + TP53 mutation EGFR mutation + TP53 mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
CD74-NRG1 fusion CD74-NRG1 fusion	Lung Adenocarcinoma LUAD	CD74-NRG1 fusion CD74-NRG1 fusion	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
YBX1 overexpression YBX1 overexpression	Lung Adenocarcinoma LUAD	YBX1 overexpression YBX1 overexpression	Lung Adenocarcinoma LUAD	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
SMARCA4 mutation SMARCA4 mutation	Lung Adenocarcinoma LUAD	SMARCA4 mutation SMARCA4 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation PBRM1 mutation	Lung Adenocarcinoma LUAD	PBRM1 mutation PBRM1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation + MSI-L/dMMR PBRM1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	PBRM1 mutation + MSI-L/dMMR PBRM1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation + TMB-L + MSI-L/dMMR BRAF mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	BRAF mutation + TMB-L + MSI-L/dMMR BRAF mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation + TMB-L + MSI-L/dMMR PBRM1 mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	PBRM1 mutation + TMB-L + MSI-L/dMMR PBRM1 mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation + MSI-L/dMMR BRAF mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	BRAF mutation + MSI-L/dMMR BRAF mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials	afatinib Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	erlotinib Resistant: C3 – Early Trials	erlotinib Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
SDC4-NRG1 fusion SDC4-NRG1 fusion	Lung Adenocarcinoma LUAD	SDC4-NRG1 fusion SDC4-NRG1 fusion	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
POLD1 C284Y POLD1 C284Y	Lung Adenocarcinoma LUAD	POLD1 C284Y POLD1 C284Y	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
MET D1010N MET D1010N	Lung Adenocarcinoma LUAD	MET D1010N MET D1010N	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
SCN8A Q225X SCN8A Q225X	Lung Adenocarcinoma LUAD	SCN8A Q225X SCN8A Q225X	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials

Lung Adenocarcinoma

Associations(456)

Associations
(456)